The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Alunbrig demonstrates reduced risk of death, disease progression in ALK+ NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III ALTA-1L trial evaluating Alunbrig (brigatinib) versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who had not received a prior ALK inhibitor demonstrated reduced risk of disease progression or death.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant.  This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...

By Jacquelyn Cobb
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account